About Opus Genetics Inc
- Industry: Biotechnology
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://opusgtx.com/
Frequently Asked Questions
What is the 52-week range for IRD?
The 52-week high is $7.07 and the 52-week low is $1.6178.
What is the P/E ratio for IRD?
The P/E ratio data is currently unavailable.
What is the dividend yield for IRD?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -316.35%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is -1091.82%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 9.03.
Analyst Recommendation Trends
Wall Street analyst consensus for IRD over the last few months:
Latest IRD News
Opus Genetics (IRD) Reports Five Early BIRD-1 Responses. Is Phase 3 Planning Justified?
Opus Genetics, Inc. (NASDAQ:IRD) reported on September 9 that all five low-dose BIRD-1 participants showed clinically meaningful improvement on at least one visual-function measure after treatment with investigational gene therapy OPGx-BEST1. The open-label Phase 1/2 cohort included three participants with Best vitelliform macular dystrophy followed for three months and two with autosomal recessive bestrophinopathy followed […]
Unusual volume stocks are being observed in Thursday's session.
In today's session, there are stocks attracting attention with their unusual volume. Let's take a closer look.
Opus Genetics: A Resounding Study Success Merits A Higher Valuation
Opus Genetics (IRD) receives a Buy rating following >30% stock surge on positive Phase 1/2 data for OPGx-BEST1 in BEST1-related retinal diseases. Click to read.
Opus Genetics, Inc. (IRD) Discusses Topline Results From Cohort 1 of BEST1 Phase I/II Gene Therapy Trial Transcript
Opus Genetics, Inc. (IRD) Discusses Topline Results From Cohort 1 of BEST1 Phase I/II Gene Therapy Trial September 9, 2026 8:00 AM EDTCompany...
Wedbush Maintains Outperform on Opus Genetics, Raises Price Target to $13
Wedbush analyst Yun Zhong maintains Opus Genetics (NASDAQ:IRD) with a Outperform and raises the price target from $10 to $13.
Sector Update: Healthcare Stocks Softer Late Afternoon
Healthcare stocks were lower late Wednesday afternoon with the NYSE Healthcare Index and the State S
Wednesday's session: top gainers and losers
Let's have a look at what is happening on the US markets one hour before the close of the markets on Wednesday. Below you can find the top gainers and losers in today's session.
IRD Stock Hits Over 5-Year Highs – Opus Genetics Experimental Therapy Shows Early Promise In Retinal Diseases Trial
Researchers observed structural improvements in the retina in four of five patients being evaluated in a Phase 1/2 study
Top stock movements in today's session.
Stay up-to-date with the latest market trends in the middle of the day on Wednesday. Explore the top gainers and losers during today's session in our detailed report.
Oppenheimer Maintains Outperform on Opus Genetics, Raises Price Target to $20
Oppenheimer analyst Andreas Argyrides maintains Opus Genetics (NASDAQ:IRD) with a Outperform and raises the price target from $10 to $20.
Opus Genetics Reports Positive OPGx-BEST1 Phase 1/2 Data, Targets Potential Phase 3 Dosing in 2027
Opus Genetics (NASDAQ:IRD) reported positive low-dose Cohort 1 data from its Phase 1/2 BIRD-1 trial of OPGx-BEST1, alongside FDA alignment on potential pivotal endpoints and a development path that could lead to Phase 3 participant dosing in 2027. Key Investor TakeawaysAll five low-dose participants showed clinically meaningful improvement in at least one measure of visual function, while four of five showed structural retinal improvements.
Gapping stocks in Wednesday's session
The market is buzzing with gapping stocks on Wednesday. Let's uncover which stocks are experiencing notable gaps during today's session.
HC Wainwright & Co. Reiterates Buy on Opus Genetics, Maintains $8 Price Target
HC Wainwright & Co. analyst Matthew Caufield reiterates Opus Genetics (NASDAQ:IRD) with a Buy and maintains $8 price target.
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers Opus Genetics (NASDAQ:IRD) shares increased by 31.7% to $5.71 during Wednesday's regular session. The company's market cap stands at $361.0 million. bioAffinity Technologies (NASDAQ:BIAF) stock
Crude Oil Jumps Over 3%; Core & Main Posts Upbeat Q2 Earnings
U.S. stocks fell Wednesday as energy rose and discretionary slumped; Signet and Opus surged, while ServiceTitan plunged. Oil jumped 3.6%.
BTIG Reiterates Buy on Opus Genetics, Maintains $12 Price Target
BTIG analyst Thomas Shrader reiterates Opus Genetics (NASDAQ:IRD) with a Buy and maintains $12 price target.
Opus Genetics Announces Positive Low Dose Cohort 1 Data from Phase 1/2 Clinical Trial of OPGx-BEST1 and Successful FDA Type C Meeting with Potential Phase 3 Dosing in 2027
OPGx-BEST1 demonstrated a favorable safety and tolerability profile with no serious adverse events or dose-limiting toxicities observed All five participants demonstrated clinically meaningful improvement in visual function, with structural improvements observed in four participants FDA aligned on ≥3 decibels microperimetry improvement in conjunction with patient reported outcomes as a potential pivotal endpoint Clinically meaningful best-corrected visual acuity improvements in 3 of 5 participan
Gene Therapy at Lower Dose Shows Vision Improvements, Opus Genetics Says
Opus Genetics posts positive Phase 1/2 trial results for OPGx-BEST1 and aligns with the FDA on Phase 3 plans for 2027.
Caleres Posts Upbeat Q2 Earnings, Joins Opus Genetics, Flotek Industries And Other Big Stocks Moving Higher On Wednesday
U.S. stocks fell, but Caleres surged 14% on strong results and higher guidance. Opus Genetics, Signet and Oddity also posted big gains.
Dow Tumbles 350 Points; Signet Jewelers Shares Jump Following Upbeat Q2 Earnings
U.S. stocks fell Wednesday, led by a 350-point Dow drop. Signet surged on strong earnings; oil, gold and silver prices climbed.
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Modular Medical (NASDAQ:MODD) shares increased by 11.3% to $3.14 during Wednesday's pre-market session. The market value of their outstanding shares is at $22.9 million. InnovAge Holding (NASDAQ:INNV)
Opus Genetics Announces Results From Low-Dose Cohort 1 Of BIRD-1, Ongoing Phase 1/2 Clinical Trial Evaluating Opgx-BEST1 Showing Favorable Safety, Tolerability Profile With No Serious Adverse Events Or Dose-Limiting Toxicities Observed
OPGx-BEST1 demonstrated a favorable safety and tolerability profile with no serious adverse events or dose-limiting toxicities observed All five participants demonstrated clinically meaningful improvement in visual
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-09-09 | Magrath George | -392,157 | - | - |
| 2026-09-09 | Magrath George | -75,541 | $5.97 | $450,980 |
| 2026-09-09 | Magrath George | +392,157 | $1.15 | $450,981 |
| 2026-09-08 | Gallagher Cam | -784,314 | - | - |
| 2026-09-08 | Gallagher Cam | +784,314 | $1.15 | $901,961 |
| 2026-09-03 | Gagnon Robert E. | -28,000 | $4.5433 | $127,212 |
| 2026-07-23 | Magrath George | -9,475 | $2.9473 | $27,926 |
| 2026-07-23 | Gagnon Robert E. | -7,783 | $2.9477 | $22,942 |
| 2026-07-23 | SCHACHLE JOSEPH K | -4,644 | $2.94 | $13,653 |
| 2026-07-23 | YERXA BENJAMIN R | -7,429 | $2.97 | $22,064 |
| 2026-05-18 | Foundation Fighting Blindness Retinal Degeneration Fund | -1,700,000 | $4.35 | $7,395,000 |
| 2026-04-23 | Zaremba Rabourn Amy | -1,641 | $5.204 | $8,540 |
| 2026-04-23 | Magrath George | -9,511 | $5.22 | $49,647 |
| 2026-04-23 | Jayagopal Ashwath | -7,542 | $5.1917 | $39,156 |
| 2026-04-23 | Gagnon Robert E. | -7,842 | $5.1846 | $40,658 |
| 2026-04-23 | SCHACHLE JOSEPH K | -4,697 | $5.2202 | $24,519 |
| 2026-04-23 | YERXA BENJAMIN R | -7,470 | $5.2371 | $39,121 |
| 2026-04-20 | Rodgers Richard J | +24,367 | - | - |
| 2026-04-20 | MANUSO JAMES S J | +24,367 | - | - |
| 2026-04-20 | Graves Adrienne L | +24,367 | - | - |
| 2026-04-20 | Gallagher Cam | +24,367 | - | - |
| 2026-04-20 | Benton Susan | +24,367 | - | - |
| 2026-04-20 | Bennett Jean | +24,367 | - | - |
| 2026-04-20 | Ainsworth Sean | +24,367 | - | - |
| 2026-03-16 | Magrath George | -24,438 | $5.2102 | $127,327 |
| 2026-03-16 | SCHACHLE JOSEPH K | -3,719 | $5.2501 | $19,525 |
| 2026-03-16 | Zaremba Rabourn Amy | -2,816 | $5.245 | $14,770 |
| 2026-03-16 | Jayagopal Ashwath | -3,719 | $5.1213 | $19,046 |
| 2026-02-12 | Jayagopal Ashwath | -5,313 | $3.39 | $18,011 |
| 2026-01-22 | Zaremba Rabourn Amy | +86,500 | - | - |
| 2026-01-22 | Magrath George | +483,639 | - | - |
| 2026-01-22 | Jayagopal Ashwath | +400,000 | - | - |
| 2026-01-22 | Gagnon Robert E. | +400,000 | - | - |
| 2026-01-22 | SCHACHLE JOSEPH K | +250,000 | - | - |
| 2026-01-22 | YERXA BENJAMIN R | +400,000 | - | - |
| 2026-01-18 | Zaremba Rabourn Amy | -3,390 | $2.1 | $7,119 |
| 2026-01-10 | Zaremba Rabourn Amy | -3,950 | $1.93 | $7,624 |
| 2026-01-06 | Gallagher Cam | +67,000 | - | - |
| 2026-01-01 | MANUSO JAMES S J | +31,188 | - | - |
| 2026-01-01 | Graves Adrienne L | +23,643 | - | - |
| 2026-01-01 | Bennett Jean | +21,127 | - | - |
| 2026-01-01 | Ainsworth Sean | +42,507 | - | - |
| 2025-12-31 | Gallagher Cam | +33,000 | - | - |
| 2025-12-29 | Gallagher Cam | +83,000 | $1.9689 | $163,419 |
| 2025-12-29 | Gallagher Cam | +81,000 | $1.9787 | $160,275 |
| 2025-12-09 | Foundation Fighting Blindness Retinal Degeneration Fund | -4,000,000 | $2.15 | $8,600,000 |
| 2025-11-01 | Magrath George | -30,350 | $2.3 | $69,805 |
| 2025-11-01 | Magrath George | -30,350 | $2.3 | $69,805 |
| 2025-10-22 | YERXA BENJAMIN R | -23,795 | $1.95 | $46,400 |